Tibor Hornyik

Tibor Hornyik

Auto-generated profile, based on publicly available information

Tibor Hornyik

Translational Cardiology, Institute of Physiology and Department of Cardiology, University of Bern

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in EP Europace
Verified
Journal Article
Open access
JLJulien Louradour
Julien Louradour
THTibor Hornyik
Tibor Hornyik
ACAlicia De la Cruz
Alicia De la Cruz
IHIrene Hiniesto-Iñigo
Irene Hiniesto-Iñigo
NANicolò Alerni
Nicolò Alerni
KOKatja E Odening
Katja E Odening
Background and aims: Loss-of-function mutations in KCNQ1 and KCNH2 (α-subunits of the slow delayed IKs and rapid delayed IKr-conducting repolarising K+ channels) lead to long QT syndrome type 1 (LQT1) and 2 (LQT2), respectively. These channelopathies present with longer action potential duration (APD) and prolonged QT interval on ECG, which can ultimately lead to deadly arrhythmias. Here we investigated the therapeutic potential of the polyunsaturated fatty acid docosahexaenoyl glycine (DHA-gly) in normalizing APD and QT interval in LQT2 by increasing IKs. Methods: The effects of DHA-gly on electrical and mechanical parameters were assessed in Xenopus laevis oocytes, wild-type (WT), LQT1 (KCNQ1-Y315S) and LQT2 (KCNH2-G628S) transgenic rabbit models, and human induced pluripotent stem cells-derived cardiomyocytes (hiPSC-CMs). Results: DHA-gly increased IKs in oocytes and WT ventricular cardiomyocytes (VCMs) in a dose-dependent manner. Consequently, DHA-gly shortened APD in vitro and QT interval ex vivo in WT and LQT2 rabbits, but not in LQT1. However, DHA-gly was unable to reduce arrhythmia formation in LQT2. Beneficial APD/QT shortening effects were accompanied by a detrimental decrease in both cellular and ventricular contraction across all genotypes, including LQT1, which could be due to a shortening in Ca2+ transient duration observed in VCMs and hiPSC-CMs. Conclusions: DHA-gly-induced IKs enhancement shows promising results in shortening APD/QT in LQT2 rabbits, while having no effect on LQT1 (impaired IKs). However, its adverse effect on cardiac contractility, even in LQT1, makes it unsuitable to treat LQTS patients. Our study highlights the importance of considering both electrical and mechanical effects of potential therapeutic compounds prior to clinical translation.

29 October 2021
Verified
Thesis
Closed access
THTibor Hornyik
Tibor Hornyik
Proarrhythmia - the triggering of arrhythmias following drug therapy - is a rare, but potentially lethal side-effect of various drugs, and therefore, a major safety concern during drug development. Most often proarrhythmia is caused by the drugs’ potential to interact with various K+-channels in the heart, leading to a prolongation of cardiac repolarization that is usually observed on the ECG as prolonged QT interval (drug-induced acquired long QT syndrome; aLQTS). Although drug-induced long-QT-related proarrhythmia is most frequently found in patients with impaired cardiac repolarization due to disease-induced structural and/or electrophysiological remodelling of the heart; most cellular, tissue and whole animal model systems used for drug safety screening are based on normal, healthy models. This approach has serious limitations; therefore, novel animal models that mimic the pathophysiological conditions under which drugs display the highest proarrhythmic risk - such as models with impaired cardiac repolarization - would be desirable for proarrhythmia safety testing. The aims of the present study: Drug-induced (HMR-1556 to block IKs) acquired LQTS, and various transgenic (congenital) LQTS rabbit models with impaired cardiac repolarization due to cardio-selective overexpression of loss-of-function mutations of human KCNH2 (HERG-G628S, α-subunit of IKr, loss of IKr, LQT2), KCNE1 (KCNE1-G52R, β-subunit of IKs, decreased IKs, LQT5)[1] or both KCNQ1 and KCNE1 transgenes (LQT2-5) were used to investigate: - the proarrhythmic potential of SZV-270, a novel antiarrhythmic drug candidate with combined Class I/B and Class III effects (acquired LQTS model). - the electrophysiological characteristics of a newly generated, double-transgenic LQT2-5 rabbit model - the utility of transgenic LQT2, LQT5 and LQT2-5 rabbit models for more reliable prediction of drug-induced ventricular arrhythmias Main findings: The acquired LQTS rabbit proarrhythmia model with pharmacologically reduced repolarization reserve (by the IKs inhibitor HMR-1556) was able to predict the known torsadogenic potential of the IKr blocker dofetilide, while indicated no SZV-270-induced proarrhythmia risk. This advantageous electrophysiological effect of the SZV-270 - prolongation of ventricular repolarization without increased arrhythmia risk - is assumed to be attributed to its combined IKr (Class III) and INa (Class I/B) blocking characteristics. Transgenic LQTS rabbit models reflected patients with clinically ‘silent’ - normal QT interval (LQT5) - or 'manifest' - prolonged QT interval (LQT2 and LQT2-5) - impairment in cardiac repolarization reserve capacity due to different pathomechanisms. The LQTS animals were more sensitive in detecting IKr - (LQT5) or IK1/IKs - (LQT2 and LQT2-5) blocking properties of drugs compared to healthy wild type (WT) animals. Impaired QT-shortening capacity at fast heart rates was observed due to disturbed IKs function in LQT5 and LQT2-5. Importantly, the transgenic LQTS models did not only show more pronounced changes in different proarrhythmia markers in response to potassium channel blockers but also exhibited higher incidence, longer duration and more malignant type of ex vivo arrhythmias than WT. Conclusions: Drug-induced and transgenic LQTS rabbit models reflect human pathophysiological settings - patients with reduced repolarization reserve - that favour drug-induced arrhythmia formation. As they demonstrate increased sensitivity to different specific ion-channel blockers (IKr-blockade in LQT5 or in HMR-1556 induced acquired LQTS model, IK1 - and IKs - blockade in LQT2 and LQT2-5), their combined use could provide more reliable, and more thorough prediction of (multi-channel-based) pro-arrhythmic potential of novel drug candidates especially in the setting of impaired cardiac repolarization reserve.